Multimodal analgesia with thoracic paravertebral block decrease pain and side effects in mastectomy patients

胸椎旁阻滞联合多模式镇痛可减轻乳房切除术患者的疼痛和副作用。

阅读:1

Abstract

BACKGROUND: Enhanced recovery after surgery (ERAS) protocols incorporating multimodal analgesia (MMA) have become increasingly popular for breast cancer surgery. Our study evaluated an ERAS approach that combined nonintubated general anesthesia (GA) with thoracic paravertebral block (TPVB) as part of the MMA and compared it with traditional GA. Postoperative outcomes were assessed using numerical rating scale (NRS) pain scores, total analgesic consumption, and postoperative nausea and vomiting (PONV). METHODS: We reviewed the medical records of 60 female patients aged 30 to 85 years who underwent unilateral mastectomy with or without sentinel lymph node biopsy (SLNB). Thirty patients received nonintubated GA with a regional block (MMA group), whereas the remaining 30 patients received conventional GA and were matched based on their anesthesia records. Postoperative analgesics, including pethidine and tramadol, were converted into intravenous morphine equivalents. We compared the groups using paired t tests for age, height, weight, operation duration, NRS scores, total analgesic dosage, and the Fisher exact test for PONV rates. RESULTS: The MMA group showed significantly lower NRS scores ( p < 0.001) and total analgesic consumption ( p < 0.001) than the GA group. Although PONV rates were lower in the MMA group (0% vs 13%, p = 0.112), this difference was not statistically significant, likely due to the effective PONV management in the GA group with dexamethasone or 5-Hydroxytryptamine type 3 (5HT-3) antagonist. There was no significant difference in pain scores ( p = 0.722) or the need for additional analgesics ( p = 0.419) between double- and triple-level TPVB. CONCLUSION: Nonintubated GA with total intravenous anesthesia (TIVA) and MMA using TPVB is a viable and safe alternative for breast cancer surgery. It results in reduced pain scores and analgesic needs compared with conventional GA, with PONV outcomes comparable to those managed with standard intravenous medications.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。